SNC 80 (Synonyms: NIH 10815) |
Catalog No.GC11355
One-Click Copy Product Info
|
A δ-opioid agonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 156727-74-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SNC 80 is a selective nonpeptide agonist of the δ-opioid receptor (Ki = 0.18 nM, IC50 = 2.73 nM) that is over 2,000-fold less effective at the μ-opioid receptor.[1],[2],[3] It effectively activates µ/δ receptor heteromers (EC50 = 52.8 nM) but not κ/δ or μ/κ heteromers.[4] SNC 80 has antinociceptive as well as pro-convulsant effects in vivo.[1],[2],[5]
Reference:
[1]. Bilsky, E.J., Calderon, S.N., Wang, T., et al. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. Journal of Pharmacology and Experimental Therapeutics 273(1), 359-366 (1995).
[2]. Calderon, S.N., Rothman, R.B., Porreca, F., et al. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A highly selective, nonpeptide δ opioid receptor agonist. Journal of Medicinal Chemistry 37(14), 2125-2128 (1994).
[3]. Knapp, R.J., Santoro, G., De Leon, I.A., et al. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. Journal of Pharmacology and Experimental Therapeutics 277(3), 1284-1291 (1996).
[4]. Metcalf, M.D., Yekkirala, A.S., Powers, M.D., et al. The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors. ACS Chem.Neurosci. 3(7), 505-509 (2012).
[5]. Danielsson, I., Gasior, M., Stevenson, G.W., et al. Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacology, Biochemistry, and Behavior 85(2), 428-434 (2006).
| Cas No. | 156727-74-1 | SDF | |
| Synonyms | NIH 10815 | ||
| Chemical Name | 4-((R)-((2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-methoxyphenyl)methyl)-N,N-diethylbenzamide | ||
| Canonical SMILES | O=C(C1=CC=C(C=C1)[C@H](C2=CC=CC(OC)=C2)N3[C@@H](C)CN(CC=C)[C@H](C)C3)N(CC)CC | ||
| Formula | C28H39N3O2 | M.Wt | 449.64 |
| Solubility | 0.2 mg/ml in DMSO, 0.2 mg/ml in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.224 mL | 11.12 mL | 22.24 mL |
| 5 mM | 444.8 μL | 2.224 mL | 4.448 mL |
| 10 mM | 222.4 μL | 1.112 mL | 2.224 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)